Rapport Therapeutics, Inc. Common Stock (NASDAQ: RAPP) is a Healthcare company (Biotechnology) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Rapport Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $23.76, Rapport Therapeutics, Inc. Common Stock trades at 56.9x sales and 2.9x book value. Over the last twelve months it generated about $20M of revenue and a net loss of $152M. It runs an operating margin of -838.1% and a net margin of -752.4%. It shows return on equity of -34.0%, return on invested capital of -41.8% and a free cash flow yield of -10.6%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 20.07. Over the past 52 weeks the share price ranged from $22.06 to $52.93, with a beta of 1.03.
Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.